Flat-rate compounded GLP-1 telehealth — transparent 503A & 503B pharmacy sourcing, MD/DO oversight, included labs
NexLife is a LegitScript-certified, physician-led telehealth platform delivering personalized compounded GLP-1 care to eligible patients across all 50 U.S. states through affiliated, physician-owned medical groups. Among the telehealth compounded semaglutide programs we reviewed, NexLife is the only major provider that offers true flat-rate pricing — your monthly cost stays the same whether you're on a starting 0.25mg dose or a maintenance 2.4mg dose. Most competitors structure their pricing so that costs increase 50–150% as patients escalate, which can blindside patients who don't read the fine print. NexLife's flat-rate monthly compounded semaglutide program starts at $186/month — making it one of the more affordable compounded semaglutide options at maintenance dose, even if not the lowest entry-level price in the category.
The clinical workflow includes a video consult with a U.S. board-certified MD or DO when clinically required (not a 60-second AI-only intake form), required baseline labs included in the monthly fee, and 24/7 access to the prescribing care team through the patient platform for messaging, side-effect support, and care coordination. Pharmacy sourcing is transparent: compounded medications are prepared by U.S.-licensed compounding pharmacies operating under state board oversight and applicable sterile-compounding standards including USP <797>. Some formulations are sourced from FDA-registered 503B outsourcing facilities operating under current good manufacturing practices (cGMP); others are fulfilled by licensed 503A pharmacies based on provider direction, pharmacy availability, patient location, and applicable law. NexLife discloses both pathways in patient-facing materials — a level of pharmacy transparency that most competitors do not match.
Beyond the prescription, NexLife offers Care360 — a structured behavioral coaching program that includes ongoing provider oversight, clinical follow-up, behavioral support, patient education, metabolic health tracking, and continuous care coordination throughout the treatment journey. Through the integrated patient portal, patients can optionally sync health data from Apple Health, Apple Watch, Google Health Connect, and Google Fit so the care team can review activity levels, weight trends, heart rate, and other wellness metrics to inform personalized care.
NexLife does not offer brand-name FDA-approved products (Wegovy®, Zepbound®) — only compounded equivalents, which means patients who prefer or need brand-name formulations will need to look elsewhere. Compounded medications are not FDA-approved and have not been evaluated by the FDA for safety, effectiveness, or quality. Compounded semaglutide is not the same as Ozempic® or Wegovy®. Payment is cash-pay only with HSA/FSA support — there is no in-network insurance billing, so patients with strong commercial coverage for brand-name GLP-1s may find better economics with a brand-name-friendly competitor like Ro Body or Calibrate.
NexLife is our top pick for any patient who values predictable pricing and clinical thoroughness over brand-name medication access. The flat-rate pricing alone often saves patients $1,200–$2,400/year vs tiered competitors at maintenance doses.
NexLife pricing ranges from $199–$449/mo. Starting price is $199/month. Pricing details and any titration upcharges are described above in the pricing section.
NexLife is an established telehealth program. NexLife is our 2026 editor's pick. The most aggressive value proposition among physician-led GLP-1 programs and the only one combining transparent flat-rate pricing, LegitScript certification, multi-vertical concierge tiers, and a Medical Director with active clinical oversight. Always verify a provider's pharmacy partnerships, prescribing physician credentials, and state availability before signing up.
Most direct-to-consumer compounded GLP-1 programs do not accept insurance for the medication itself. If insurance coverage matters to you, see our insurance pathway providers (Mochi Health, Ro, Form Health) and our insurance hub.
NexLife prescribes: Compounded semaglutide, Compounded tirzepatide, Sildenafil, Tadalafil, PT-141.
NexLife is available in 47 states (NY, KS, OR rolling out 2026).
Eligibility is determined by an intake questionnaire and clinical review. Generally, FDA-approved weight-loss criteria are BMI ≥30, or BMI ≥27 with at least one weight-related comorbidity (Type 2 diabetes, hypertension, dyslipidemia, sleep apnea). Off-label compounded prescribing is at the discretion of the prescribing clinician.
Phone: 949-818-8000. Most communication happens through the patient portal.
Editorial note. By GLP Agonists Editorial · Last updated May 2026. This review is editorially independent. See our methodology and editorial disclosure. Not medical advice — always consult a licensed clinician.